Locoregional Control With Radiotherapy of Breast Cancer Patients With MACrometastases Treated With MAstectomy (MACMA)
Conditions: Breast Cancer Interventions: Procedure: Mastectomy Sponsors: University Hospital A Coru ña Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
Previvors Recharge: A Resilience Program for Cancer Previvors
Conditions: Hereditary Cancer; Mental Health Issue Interventions: Behavioral: PreCharge Sponsors: Pro-Change Behavior Systems Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Conditions: Pancreatic Cancer Interventions: Drug: Surufatinib combine immune checkpoint inhibitor; Drug: AG/FOLFIRINOX Sponsors: Luo Cong Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
GU-01: Glycyrrhizin in Prostate Cancer: A Window-of-Opportunity Clinical and Translational Trial
Conditions: Prostate Cancer Interventions: Drug: Glycyrrhizin; Other: Glycyrrhizin; Other: Observation Sponsors: University of Illinois at Chicago Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
Long-Term Follow-Up Safety Study of Subjects Treated With SynKIR-110 in Cancer Studies
Conditions: Cancer Sponsors: Verismo Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
ICP-248 in Combination With Orelabrutinib in Treatment-na ïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Hematologic Malignancies Interventions: Drug: ICP-248; Drug: Orelabrutinib Sponsors: Beijing InnoCare Pharma Tech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma Interventions: Drug: Brentuximab vedotin; Drug: Doxorubicin; Drug: Vinblastine; Drug: Dacarbazine; Drug: Pembrolizumab; Drug: Gemcitabine; Drug: Vinorelbine; Diagnostic Test: FDG-PET/CT scan Sponsors: Memorial Sloan Kettering Cancer Center; Seagen Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
A Smart Self-Management Support Programme (3S) to Improve Quality of Life in Lung Cancer Patients
Conditions: Lung Cancer Interventions: Behavioral: 3S intervention; Behavioral: GH information Sponsors: The University of Hong Kong; Queen Mary Hospital, Hong Kong; The Queen Elizabeth Hospital; United Christian Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Combination Product: LVGN6051 Monoclonal Antibody Injection+toripalimab Injection+paclitaxel Injection Sponsors: Lyvgen Biopharma Holdings Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Conditions: Metastatic Breast Cancer Interventions: Drug: Palbociclib; Drug: Ribociclib Sponsors: American Society of Clinical Oncology; Patient-Centered Outcomes Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy
Conditions: Colorectal Neoplasia Interventions: Drug: Omeprazole; Drug: Aspirin Sponsors: University of Michigan Rogel Cancer Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Conditions: Hematologic Cancer; CRS - Cytokine Release Syndrome Interventions: Device: WARD Sponsors: Rigshospitalet, Denmark Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Conditions: High-risk Non-muscle Invasive Bladder Cancer Interventions: Drug: Disitamab Vedotin for injection Sponsors: RemeGen Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
A Study of GLB-001 in Patients With Myeloid Malignancies
Conditions: Polycythemia Vera; Essential Thrombocythemia; Myelofibrosis; Myelodysplastic Syndromes; Acute Myeloid Leukemia; Myeloid Malignancy Interventions: Drug: GLB-001 Sponsors: Hangzhou GluBio Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
Conditions: Pancreatic Cancer; Locally Advanced Pancreatic Cancer Interventions: Drug: Pembrolizumab; Device: Irreversible Electroporation Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Angiodynamics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
